Lenalidomide and Low Dose Dexamethasone Plus Elotuzumab or Carfilzomib for Relapsed or Refractory Multiple Myeloma: A Comparison of Progression-Free Survival with Reconstructed Individual Participant Data.
Shuo LiXiang-Yu MengSouraka Tapara Dramani MamanYong-Nong XiaoSheng LiPublished in: BioMed research international (2018)
The CLD regimen may result in better PFS as compared with the ELD regimen in RRMM patients.